by EmpathiCSubstanceS | Mar 8, 2023 | Addiction, Alcoholism, Anxiety, DMT, Iboga, LSD, Psychedelic Medicine
Variations in a crucial receptor’s genetics led to differences in efficacy and potency for four psychedelic drugs. Researchers in North Carolina have found evidence that people’s genes may affect how they trip on psychedelic drugs. The finding may be a potential...
by EmpathiCSubstanceS | Aug 17, 2022 | LSD, Psychedelic Research
CEQ scores were negatively associated with emotional stability scores (the inverse of neuroticism) in Study 1 and positively associated with neuroticism scores in Study 2. Neuroticism may contribute to the strength of challenging experiences with psychedelics in...
by EmpathiCSubstanceS | Aug 17, 2022 | LSD, Psychedelic Research
In total, 1116 of the respondents were either currently microdosing (79.5%) or microdosed in the past (20.5%). LSD (10 mcg) and psilocybin (0.5 g) were the most commonly used psychedelics with a microdosing frequency between two-to-four times a week. The majority of...
by EmpathiCSubstanceS | Aug 17, 2022 | LSD, Psychedelic Research
The model identified the causative mechanisms for the non-linear interactions between the neuronal and neurotransmitter system, which are uniquely linked to (1) the underlying anatomical connectivity, (2) the modulation by the specific brain wide distribution of...
by EmpathiCSubstanceS | Aug 17, 2022 | LSD, Psychedelic Research
343 respondents, mostly White (89%), males (78%), in the USA (60%) completed the survey. Participants reported seven years of problematic alcohol use on average before the psychedelic experience to which they attributed reduced alcohol consumption, with 72% meeting...
by EmpathiCSubstanceS | Aug 17, 2022 | LSD, Psychedelic Research
A wide-range of benefits was reported, including: help with mood disorders, addictions and migraine as well as more general long-term improvements in wellbeing. Symptoms of hallucinogen persisting perceptual disorder were reported by a number of subjects and these...
